MARKET

VYNT

VYNT

Vyant Bio Inc
NASDAQ
0.6017
-0.0514
-7.87%
Opening 11:27 03/21 EDT
OPEN
0.7196
PREV CLOSE
0.6531
HIGH
0.7297
LOW
0.6017
VOLUME
4.78K
TURNOVER
766
52 WEEK HIGH
9.85
52 WEEK LOW
0.6000
MARKET CAP
3.56M
P/E (TTM)
0.0880
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 02/14 13:06
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 02/03 17:31
HC Wainwright & Co. Downgrades Vyant Bio to Neutral
Benzinga · 02/03 14:28
BRIEF-Vyant Bio Inc Says Under Cash Preservation Plan Of Jan 31, Co Sees To Incur About $1.4 Mln For Employee Termination-Related Costs In Q1, Q2 Of 2023
Reuters · 02/03 12:42
Vyant CEO to step down as board plans to reduce workforce, explore alternatives
Seeking Alpha · 02/03 11:44
--HC Wainwright Downgrades Vyant Bio to Neutral From Buy
--HC Wainwright Downgrades Vyant Bio to Neutral From Buy
MT Newswires · 02/03 11:34
Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway
Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway
MT Newswires · 02/03 07:37
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 01/12 21:31
More
About VYNT
Vyant Bio, Inc. (Vyant Bio) is a biotechnology drug discovery company focused on identifying unique biological targets and novel and repurposed therapeutics. Vyant Bio is also focused on combining sophisticated data science capabilities with highly functional human cell derived disease models. Vyant Bio’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. The Company’s platform is designed to elucidate disease pathophysiology; formulate key therapeutic hypotheses; identify and validate drug targets, cellular assays, and biomarkers to guide candidate molecule selection, and guide clinical trial patient selection and trial design. Vyant Bio’s programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 Deficiency Disorders (CDD) and familial Parkinsons Disease (PD).

Webull offers kinds of Vyant Bio Inc stock information, including NASDAQ:VYNT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYNT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VYNT stock methods without spending real money on the virtual paper trading platform.